Loading clinical trials...
Loading clinical trials...
Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers
Conditions
Interventions
eribulin mesylate
Locations
1
United States
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
May 8, 2012
Primary Completion Date
August 23, 2017
Completion Date
August 23, 2017
Last Updated
September 28, 2018
NCT00939627
NCT01847326
NCT00470496
NCT01469429
NCT02035527
NCT00095628
Lead Sponsor
University of Washington
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions